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Abstract. Cirrhosis is the final stage of most of chronic liver diseases, and is almost invariably complicated by portal hypertension,
which is the most important cause of morbidity and mortality in these patients. This review will focus on the non-invasive methods
currently used in clinical practice for diagnosing liver cirrhosis and portal hypertension. The first-line techniques include physical
examination, laboratory parameters, transient elastography and Doppler-US. More sophisticated imaging methods which are less
commonly employed are CT scan and MRI, and new technologies which are currently under evaluation are MR elastography and
acoustic radiation force imaging (ARFI). Even if none of them can replace the invasive measurement of hepatic venous pressure
gradient and the endoscopic screening of gastroesophageal varices, they notably facilitate the clinical management of patients
with cirrhosis and portal hypertension, and provide valuable prognostic information.
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1. Introduction
Portal hypertension is a key event in the evolution of
chronic liver disorders when severe fibrosis or cirrho-
sis develops. Once portal pressure exceeds 10 mmHg
(clinical significant portal hypertension – CSPH), pa-
tients are at risk of experiencing severe complications
such as variceal bleeding or ascites. In patients with
chronic liver disease, histopathological examination of
biopsy samples has traditionally been considered the
gold standard for staging the severity of fibrosis and
for diagnosing progression to cirrhosis. However, liver
biopsy has important limitations (it is invasive and sam-
pling error is very frequent),and in the last decademany
studies have been devoted to the search of non-invasive
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methods to diagnose fibrosis and cirrhosis. The ideal
test for fibrosis and cirrhosis diagnosis should be safe,
easy to perform, inexpensive, reproducible (within pa-
tients and between and within laboratories) and should
provide an accurate assessment of the degree of liver
fibrosis from pre-cirrhotic scarring, through very early
and early compensated cirrhosis. The test should be
predictive of long term outcomes such as portal hyper-
tension, decompensation, need for transplantation, and
death.
On the other hand, HVPG measurement is the gold
standard technique to evaluate the presence and sever-
ity of portal hypertension. Also in this case some limi-
tations exist, since HVPG measurements are not avail-
able in all centers, the technique is invasive and some
patients are unwilling to be submitted to it. This is even
more relevant when the repetition of the procedure is
needed to monitor treatment response. These issues
have raised interest to non-invasively determine when
CSPH is present, so allowing defining a patient at risk of
developing portal hypertension-related complications.
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The aim of this review is to depict the non-invasive
tools used to diagnose and monitor treatment of cirrho-
sis and portal hypertension (Table 1).
2. Physical examination
The cheapest and readily available information to
detect cirrhosis and/or of portal hypertension is that ob-
tained by physical examination (Fig. 1). Physical stig-
mata of liver cirrhosis are: a firm left hepatic lobe [1],
gynaecomastia, testicular atrophy, parotidomegaly, fea-
tures of hepato-cellular failure such as jaundice, vascu-
lar spiders, leuconykia, palmar erythema or of hepatic
encephalopathy, presence of abdominal wall collater-
al circulation, ascites, leg oedema and splenomegaly
(which can be considered the single most important
clinical diagnostic sign of portal hypertension). In ad-
dition, hypotension and tachycardia may be found re-
flecting the frequent hyperdynamic circulation found
in patients with cirrhosis.
All these findings can be found in decompensated
disease with features of portal hypertension, and are
obviously highly specific of the syndrome [2]. How-
ever, decompensated cirrhosis does not represent the
population where non-invasive diagnosis is more need-
ed, and unfortunately, the sensitivity of physical signs
in patients with compensated cirrhosis is low.
As for CSPHdetection, in a recent study by our group
performed in a homogeneous population of patients
with well compensated cirrhosis in which HVPG was
measured, none of the physical signs was useful to
identify patients with HVPG over 10 mmHg. On the
other hand spider naevi were independently predictive
of esophageal varices [3].
3. Laboratory tests
Serum markers of fibrosis have the advantage over
liver biopsy of offering a sampling of the all liver,allow-
ing frequent repetition, being far less invasive and hav-
ing less dependence on professional expertise. More-
over, as we will discuss below, they may reflect the
severity of liver fibrosis and predict clinically relevant
outcomes. In the following we will focus on the ability
of these tests to detect cirrhosis appearance. It is out
the scope of the review to analyze in depth the utility
of these tests in grading fibrosis.
3.1. Indirect markers of fibrosis (Class II, simple
laboratory tests)
The diagnostic performance of single or combined
hematological and biochemical parameters routinely
available, which may “indirectly” reflect (surrogate
markers) the effect of fibrosis on the liver has been ex-
tensively studied. These include indicators of cytolysis
(AST, ALT), cholestasis (γGT, bilirubin), hepatocytes
synthetic function (i.e. INR, cholesterol, ApoA1, hap-
toglobin, N-glycans), and hypersplenisms due to por-
tal hypertension (i.e. platelet count). These parame-
ters may also be surrogates of inflammation and steato-
sis, which have a significant predictive value for the
progression of fibrosis [4,5].
About 20 numerical scores or indices are report-
ed for parameters which are mostly routine laborato-
ry tests and frequently multiparametric. Among them,
Fibrotest and AST to Platelet ratio index (APRI) have
been proposed for clinical application [6,7]. The Fi-
broTest, which is a combination of α2-macroglobulin
(α2M), ApoA1, Bilirubin, γGT, Haptoglobinmeasure-
ments, is the most validated indirect test for liver fibro-
sis [8–10]. It has been shown to accurately predict the
presence of severe fibrosis/cirrhosis with an AUC of
0.92. APRI has also been found to be a reliable predic-
tor of severe fibrosis/cirrhosis in patients with chronic
hepatitis C (AUC: 0.80) [11].
However, a recent meta-analysis of 14 studies exam-
ining 10 panels of indirect blood markers in chronic
hepatitis C [12], including Fibrotest and APRI, demon-
strated that in individual patients they cannot reli-
ably differentiate stages of fibrosis. This makes non-
invasive markers of fibrosis still insufficient to “mon-
itor” the evolution of chronic liver diseases. In addi-
tion, accuracy of serum markers may be reduced by
multiple factors, such as co-morbidity of the patients
(connective tissue disease among others) and ongoing
drug therapies.
As for portal hypertension, Child-Pugh score and its
objective component (albumin, bilirubin, INR) corre-
late with HVPG [13–15] and with the prevalence and
grade of esophageal varices in cirrhotic patients. Inter-
estingly this correlation is observed also in patientswith
compensated cirrhosis [3], suggesting that a close re-
lationship exists between the structural changes which
give onset to portal hypertension and hepatocellular
dysfunction. In our study, amodel obtained by the com-
bination of biochemical parameters, namely albumin,
ALT, and INR, had an area under the curve (AUROC)
of 0.952 in the prediction of CSPH [3].
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Table 1
Non invasive methods currently available to diagnose cirrhosis and portal hypertension. As shown, none of them holds all the characteristics of an
ideal method; however, their combination might help overcome the limitation of the individual tests. Nonetheless a “portal sphygmomanometer”
is not yet available
Characteristics needed for an ideal non-invasive method
Safe Quantitative Accurate Objective Reproducible Cheap Validated
Non-invasive Physical examination +++ − − ++ ++ +++ ++
methods Standard +++ +++ + +++ +++ ++ +++
available for Laboratory
diagnostic/ Tests
prognostic Direct serum markers of +++ +++ ++ +++ +++ − ++
purposes in fibrosis
patients with Transient elastography +++ +++ ++ +++ ++ ++ ++
portal Ultrasound and Doppler- +++ + + + + +++ +++
hypertension Ultrasound
Abdominal
CT-scan
+ (*) + ++ ++ +++ + ++
Abdominal MRI ++ + ++ ++ +++ + ++
*Cumulative radiation exposure and subsequent risk should be carefully evaluated [78].
Fig. 1. Proposed algorithm for the non-invasive diagnosis of cirrhosis and portal hypertension. As shown, in indeterminate cases requiring liver
biopsy the transjugular modality has to be preferred since this allows the simultaneous measurement of the HVPG. If hepatic vein catheterization
is not available a percutaneous liver biopsy should be obtained.
Platelet count is independently correlated with the
prevalence and grade of esophageal varices in several
studies [16,17], and platelet count to spleen diameter
ratio> 909 had a 100%negative predictive value for the
presence of esophageal varices in one study [18] sug-
gesting that it could be of help in avoiding unnecessary
endoscopies; however in subsequent series its predic-
tive value was lower, and should be further investigated
before being accepted in clinical practice.
3.2. Direct markers of fibrosis (Class I)
Class I markers, also called direct or true markers,
are biochemical parameters measurable in the periph-
eral blood that express liver matrix constituents or en-
zymes involved in their regulation,which allow a quan-
titative assessment of the total amount of hepatic ex-
tracellular matrix, and its deposition or removal [19].
Their determination is expensive, and the ability of sin-
gle markers in the assessment of the severity and pro-
gression of liver fibrosis is poor. A systematic review
of serum markers of liver fibrosis concluded that panels
of markers evaluated in combination are more accurate
than single tests [20].
The European Liver Fibrosis (ELF) study evaluated
the relationship between different algorithms incorpo-
rating serum levels of a panel of direct markers and in-
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dividual histology scores in 1000 patients with a wide
range of chronic liver disease [21]. Overall, the algo-
rithm discriminant score allowed a good differentiation
between patients with and without cirrhosis at biopsy
and might be a promising approach in the future.
3.3. Panels combining direct and indirect markers
Some scores combine direct and indirect non-
invasive markers to diagnose significant fibrosis or
cirrhosis. For example, Fibrometer [22] includes
platelets, prothrombin time, AST, α2M, age, urea and
hyaluronan (HA), and Hepascore [23] includes biliru-
bin, γGT, TIMP-1, α2M, age, and sex. Prospective
evaluation [24] has shown improved accuracy of Fi-
brometer compared to Fibrotest, in particular in diag-
nosing severe fibrosis and cirrhosis, but further external
validation is needed.
3.4. Prognostic value of serum markers
Serum markers showed predictive value for liver-
related morbidity and mortality.
The results from ELF study in a subgroup of 120
patients followed-up for 5–8 years suggest that serum
markers of fibrosis are as good as liver histology in the
prediction of liver related death. In this study, the sen-
sitivity of F3-F4 fibrosis at enrolment in the prediction
of liver-related mortality at 8 years was 80.7%, while
that of serum markers was 84.0%. In a study in patients
with alcoholic liver disease [25],Nojgaard reported that
YKL-40 and collagen propetidePIIINP were predictive
of short survival and increased relative risk of death.
In a cohort of patients with primary biliary cirrhosis
treated with UDCA [26], HA was the only independent
predictor of poor outcome.
Some studies evaluated the prognostic value of serum
markers of fibrosis in patients with cirrhosis. Gue-
chot and colleagues looked at the predictive value of
Hyaluronic acid (HA) in a series of patients with HCV-
cirrhosis, followed-up for a median of 38 months [27].
In this study, HA had a predictive value equivalent to
Child-Pugh score for the prediction of severe compli-
cations of cirrhosis or death.
4. Transient Elastography (TE)
Transient elastography (measured by Fibroscan ,
Echosens, Paris, France) has been recently developed
for the non-invasive assessment of liver stiffness. Mea-
surements are performed with an ultrasound transducer
probe built on the axis of a vibrator; a vibration of mild
amplitude and low frequency is transmitted, inducing
a wave that propagates through the liver tissue, and
pulse-echo acquisitions are performed to measure the
velocity of propagation of the wave, which is direct-
ly related to the tissue stiffness. The volume of liver
parenchymawhich can be studied by Fibroscan is about
100 times greater than that obtained by biopsy, and has
therefore a potentially lower sampling error.
Since fibrosis within the liver increases the organ’s
stiffness, TE has been used to assess the presence of
fibrosis and cirrhosis, and has proved an excellent tool
in this setting [28]. Liver stiffness has been shown
to correlate with fibrosis severity in HCV [29], and in
other chronic liver disease [30]. The best cut-off to
detect cirrhosis is not exactly defined since it appears to
vary according to the etiology of liver disease; however,
in a recent prospective study performed in patients with
liver disease values over 12.5 kPa strongly suggested
cirrhosis [31].
The value of TE in the non-invasive prediction of
portal hypertension has also been evaluated. In a study
performed in patients with hepatitis C recurrence after
liver transplantation, liver stiffness showed an excellent
correlation with fibrosis and with HVPG [32]. In this
study, a liver stiffness value 8.74 kPa had a sensitivity
and specificity of 90% and 81% for the diagnosis of
any grade of portal hypertension (HVPG 6 mm Hg).
In addition, in the setting of cirrhosis, liver stiffness
has been shown to correlate with the presence of large
esophageal varices; specifically, in the study by Kaze-
mi and colleagues, a liver stiffness value above 19 kPa
predicted the presence of large esophageal varices [33].
In another study published as an abstract [34] the au-
thors found a good direct correlation between HVPG
and liver stiffness in a population of uncomplicated al-
coholic and HCV-related cirrhotic patients; a cut-off
value of 17 kPa had a sensitivity of 90% for the diag-
nosis of HVPG over 12 mmHg. In two additional stud-
ies the cut-off values of respectively 23 and 13.6 kPa
had a good capacity to predict the presence of CSPH
in patients with chronic liver disease [35,36]. It should
be underlined that in the study by Vizzutti et al. [35], it
was shown that above the threshold value of 13.6 kPa
there was not a good correlation between liver stiffness
and HVPG, probably since once portal hypertension
increases above a the threshold HVPG value of 10–
12 mmHg porto-systemic collaterals develop and fibro-
sis is no longer the only mechanisms inducing portal
hypertension, since increase of porto-collateral blood
flow importantly contributes [35].
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Table 2
Main ultrasonographic signs of cirrhosis and portal hypertension
Refs Sensitivity Specificity
US signs of cirrhosis
Liver Nodular liver surface (42;45;79;80) 55–91% 82–95%
Coarse echopattern (81;82) 20% overall
51% HBV-HDV
90%
Left lobe/ right lobe ratio > 1.30 (83) 74% 100%
Caudate lobe/ right lobe ratio 0.65 (hypertrophy of caudate lobe) (84) 43–84% 100%
Reduction of the medial segment of left hepatic lobe (85) 74% 100%
Hepatic Narrowing and loss of normal phasicity of flow by Doppler (86) Not reported Not reported
veins Altered straightness
Nonuniformity of hepatic vein wall echogenicity
(87) 97%
88%
91% 86%
Hepatic
artery
Increased diameter (88) Not reported Not reported
US signs of portal hypertension
Portal Dilatation of portal vein ( 13 mm) (16;47) < 50% 90–100%
venous Reduction of portal vein blood flow velocity (Max vel < 16 cm/s;) (89;90) 80–88% 80–96%
system mean vel < 13 cm/ s
Inversion of portal vein blood flow (91)d}2} Not reported; sign
prevalence: 8.3%
of unselected pts
100%
Increased portal vein congestion index ( 0.08) (49;90) 67–95% 100%
Dilatation of splenic vein (SV) and superior mesenteric vein (SMV)
( 11 mm)
(92;93) 72% 100%
Reduction of respiratory variation of diameter in SV or SMV (<
40%)
(47) 79.7% 100%
Spleen Splenomegaly (diameter > 12 cm and/or area 45 cm2 (3) 93% 36%
Splenic
artery
Increased resistive index of the intraparenchymal branches ( 0.60) (94) 84.6% 70.4%
Hepatic
artery
Increased resistive index of artery at the porta hepatis (> 0.78)
Increased resistive index of the intrahepatic branches
(95) 50% 100%
Renal
artery
Increased resistive index of the right interlobar renal artery ( 0.65) (94) 79.5% 59.3%
SMA Decrased pulsatility index ( 2.70) (94) 85.7% 65.2%
Presence of porto-systemic collateral circulation (58) 83% 100%
In a study recently performed in our unit, TE was
tested for the diagnosis of CSPH in the setting of pa-
tients with potentially resectable hepatocellular carci-
noma. The results suggested that TE is not an ideal
method to rule-out or confirm CSPH in this population,
and should not be used as a non-invasive surrogate for
indicating or contraindicating surgery [37].
Given these observations, it can be suggested that
even if high values of liver stiffness at TE are strongly
predictive of cirrhosis and of the presence of CSPH, the
technique is not accurate enough to assess the severity
of portal hypertension.
5. Ultrasound and colour-Doppler-ultrasound
Ultrasonography (US) is a non-invasive and inex-
pensive technique frequently used as first line examina-
tion in the diagnosis and follow-up of hepatic diseases
(Fig. 1).
Doppler-US is very accurate in diagnosing throm-
bosis in large vessels. Therefore, it is extremely use-
ful to identify causes of portal hypertension different
than cirrhosis, such as portal vein and hepatic veins
thrombosis, and should be performed routinely for this
purpose at the beginning of the diagnostic work-up of
cirrhosis and portal hypertension [38–40].
Findings of cirrhosis on conventional US include
changes in liver morphology and signs of portal hy-
pertension (Table 2). US findings are usually highly
specific, and can be considered sufficient to confirm the
diagnosis [41], so a positive result “rules-in” cirrho-
sis. On the other hand, the sensitivity of individual US
findings is low, indicating that a negative result cannot
fully rule-out cirrhosis.
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The most accurate single sign for the diagnosis of
cirrhosis, which can be found even in early phases, is
nodularity of liver surface [42]; this should be specif-
ically investigated. The use of high frequency trans-
ducers increases the diagnostic performance of conven-
tional abdominal US probes, and should be preferred.
Few false positive have been described [43].
The combination of nodular liver surface and portal
vein mean velocity below 12 cm/s holds 80% accuracy
for discriminating between patients with chronic hep-
atitis with severe fibrosis and those with cirrhosis [44].
In patients with clinical suspicion of cirrhosis and
confounding conditions the detection of nodular liver
surface is an excellent non-invasive method to rule-
in cirrhosis, while the combination of US and tran-
sient elastography allows the best diagnostic perfor-
mance [45].
As for the assessment of portal hypertension in cir-
rhosis, all US signs of portal hypertension are very spe-
cific, while their sensitivity is low, especially in com-
pensated cirrhosis; therefore, while the presence of a
sign or a combination of signs definitely rules-in portal
hypertension, its absence cannot exclude the diagnosis.
Spleen dimension is the US sign most commonly
associated to the presence of portal hypertension; con-
trarily to other signs its sensitivity is high, while its
specificity ranges 50–80%according to different series.
It is an independent predictor of esophageal varices,
and is associated to CSPH in compensated cirrhotic
patients [3].
The presence of porto-collateral circulation such as
paraumbilical vein, spontaneous spleno-renal circula-
tion, dilated left and short gastric veins, and the inver-
sion of flow within the portal system are 100% specific
US signs of CSPH.
Other US signs of CSPH include dilatation of portal
vein (diameter > 13 mm) [46]; lack or reduced res-
piratory variations of splenic and superior mesenteric
vein diameter [47]; reduced portal vein velocity (max-
imal and mean velocimetry of portal vein flow, respec-
tively < 16 cm/s and < 10–12 cm/s) [48]; increased
congestion index of portal vein [49]; altered hepatic
venous Doppler pattern [50]; increased intraparenchy-
mal hepatic and splenic artery impedance [51–53]; in-
creased intraparenchymal renal artery impedance [54]
and reduced mesenteric artery impedance [55].
HVPG significantly correlates with some US param-
eters such as portal vein velocity and volume of blood
flow [55], hepatic artery resistance index, splenic and
renal artery resistance and pulsatility index. However
the degree of correlation is only slight to moderate and
these parameters can not be used as reliable surrogates
of HVPG.
Some US-Doppler parameters hold prognostic value
in cirrhosis.
As for the presence of varices and variceal for-
mation, growth and bleeding, models for the predic-
tion of varices of any size or of large varices in-
clude portal vein diameter or spleen size in combi-
nation with blood tests (platelet count and prothrom-
bin time). Prospective studies in compensated cir-
rhosis [56,57] initially suggested a good discriminat-
ing ability. Nonetheless, validation studies in sub-
sequent series failed to confirm an adequate accura-
cy for varices prediction. Porto-systemic collaterals
such as left gastric vein > 3 mm and short gastic
veins (collaterals at upper spleen half) strongly sug-
gest the presence of esophageal varices [58], and their
development/increase in number have been associat-
ed with a greater proportion of variceal formation and
growth [59]. Similarly, progressive spleen enlargement
may predict variceal formation and growth [60].
Congestion index of the portal vein (ratio between
the cross-sectional area and blood flow velocity) inde-
pendently predicted first variceal bleeding in a prospec-
tive study in patients with varices [61].
As for the prediction of first clinical decompensation
of any kind, spleen enlargement (> 1 cm) on follow-
up might be associated with a higher probability of
developing the first clinical decompensation of cirrho-
sis [60].
A portal vein averaged maximum velocity <15 cm/s
was the only variable independently associated with a
high risk of non-malignant portal vein thrombosis in a
recent prospective study [62].
The presence of porto-systemic collateral circula-
tion predicted hepatocellular carcinoma appearance in
a recent study performed in 129 unselected cirrhotic
patients [63], probably since porto-systemic collater-
als are signs of clinically significant portal hyperten-
sion, which is independently related with HCC occur-
rence [64].
US is highly sensitive in diagnosing ascites, which is
the most common clinical decompensation of cirrhosis
and holds a severe prognostic significance.
The increase of intrarenal arteriolar RI in patients
with cirrhosis is related to arterial vasoconstriction; it
is observed in about 40% of patients with ascites, is
accurate for detecting hepato-renal syndrome [65].
A small liver size, spleen size over 14.5 cm, mean
portal vein velocity below 10 cm/s and loss of pul-
satility of hepatic veins have been associated to higher
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mortality on follow-up in patients with compensated
cirrhosis [66].
Monitoring of treatment of portal hypertension.
There is currently no room for performing US-Doppler
monitoring of HVPG response to medical therapy of
portal hypertension, since changes of Doppler param-
eters do not accurately reflect changes in HVPG [66].
However, in a recent study, CDUS pattern at baseline
was shown to be different, showing a greater base-
line splanchnic vasodilatation (as indicated by a low
pulsatility and resistance index in splenic, mesenteric
and hepatic artery) in HVPG non-responders than in
responders after chronic nadolol treatment [67], and
overall the high negative predictive value of Doppler
parameters may help to detect non-responders.
On the other hand, US-Doppler is useful in the non-
invasive follow-up of transjugular intrahepatic porto-
systemic shunt (TIPS), and allows saving unnecessary
invasive hemodynamics procedures [68].
6. Second line imaging techniques and new
methods needing validation
Computed tomographic scan (CT) and magnetic
resonance (MRI) allow an accurate visualization of
the liver parenchyma and the portal venous system.
Three studies demonstrated that single detector or
multidetector CT scanning are reliable in detecting
large esophageal varices (specificity 90–100%and sen-
sitivity 84–100%), with moderate inter-observer vari-
ability; however the sensitivity for small varices de-
tection is lower. A cost-effectiveness analysis showed
that straight CT screening of varices was more cost-
effective than endoscopy screening and than CT fol-
lowed by endoscopy for patients with small varices on
CT [69].
Dynamic contrast-enhanced single-section CT scans
and MRI (compartmental analysis of intensity versus
time curves for magnetic resonance images of the liv-
er after injection of a gadolinium chelate), and phase
contrastMR angiographyallow a quantitativemeasure-
ment of portal [70] and azygos [71] blood flow. Azy-
gos blood flow, as measured by MRI, correlates with
the presence of esophageal varices at endoscopy, and
with the risk of bleeding from varices. Portal fraction
of liver perfusion and mean transit time at MRI have
been recently showed to have a good correlation with
HVPG [72]. Whether any of these sophisticated and
expensive techniques add to clinical, biochemical, US
or transient elastography parameters should be evalu-
ated in future studies.
MR elastography (MRE) is a novel method pro-
posed to evaluate liver stiffness. The measurement is
obtained by synchronizing motion-sensitive imaging
sequences with the application of acoustic waves in tis-
sue media [73]. It has been tested in human subjects,
and the preliminary results support its practicability in
predicting the stage of fibrosis in patients with chronic
liver disease [74]. MRE is repeatable and changes cor-
relate well with changes in tissue fibrosis [75]. MRE
has been successfully applied to measure spleen stiff-
ness, which was highly correlated with hepatic stiff-
ness and might have a closer correlation with portal
pressure [76].
Although MR elastography has some technical ad-
vantage over Fibroscan (no need an acoustical window,
a freely-oriented field of view, lack of sensitivity to
body habitus) it is more expensive and time consum-
ing and it will only be used as an additional tool in
patients that already need to be submitted to MRI for
other reasons.
Acoustic radiation force impulse imaging (ARFI)
is a novel technology that provides information about
the local elasticity of tissues in real-time. Short-
duration (∼ 262 μs) acoustic pulses are produced and
induce the propagation of shear waves which generate
minimum displacements within the target tissue. The
shear wave velocity (metres per second) is measured
in a small portion of the parenchyma (10 mm long ×
6 mm wide). It has the advantage of being integrated in
a conventional ultrasound system, so allowing control-
ling the sampling position within the liver. Recent data
suggest that ARFI is as accurate as transient elastogra-
phy by Fibroscan for fibrosis and cirrhosis detection in
patients with chronic liver diseases [77].
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